Quadrature Capital’s Lucid Diagnostics LUCD Stock Holding History

Quadrature Capital’s Portfolio LUCD Stock Details LUCD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-15,801	Closed	-$17.2K	–	1664
2025 Q4	$17.2K	Buy	+15,801	New	+$17.7K	﹤0.01%	1213
2025 Q3	–	Sell	-24,917	Closed	-$28.7K	–	1300
2025 Q2	$28.7K	Buy	+24,917	New	+$32.2K	﹤0.01%	982

Other funds holding LUCD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

MCM

Masters Capital Management Atlanta, Georgia $3.03B AUM 57.21% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

PCM

Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return

Quadrature Capital's LUCD Position: Q1 2026 in Review

Quadrature Capital sold out of Lucid Diagnostics (LUCD) in Q1 2026, closing a stake of 15,801 shares — an estimated $17.2K sold.

Quadrature Capital first reported a position in LUCD in Q2 2025 and held it in 2 quarters. The position peaked at $28.7K in Q2 2025. 103 funds tracked by Wall St. Rank hold LUCD as of Q1 2026.

Quadrature Capital reported no remaining Lucid Diagnostics position as of Q1 2026 after selling out during the quarter.
Quadrature Capital sold 15,801 Lucid Diagnostics shares in Q1 2026, an estimated $17.2K.
Quadrature Capital first reported a position in Lucid Diagnostics in Q2 2025 and held it in 2 quarters.
Quadrature Capital's Lucid Diagnostics position peaked at $28.7K in Q2 2025.
103 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q1 2026.

Based on Quadrature Capital's 13F filing for Q1 2026, filed 15 May 2026.